Highlights
Long-term follow-up of participants from 14 randomized controlled trials found no detectable difference in self-reported serious health outcomes between active immunotherapy and placebo groups. Reported outcomes included hypoglycemia, hospitalization, serious infections, autoimmune disease, allergic reactions, and cancer. Although the findings are reassuring, the authors emphasize that continued surveillance remains important because most participants contributed only a few years of follow-up and some outcomes are rare.
Clinical context
Type 1 diabetes is an immune-mediated disease characterized by destruction of pancreatic beta cells, leading to lifelong insulin dependence. Because the disease is driven by immune dysfunction, immunotherapy has long been investigated as a strategy to preserve beta-cell function, delay progression, or alter disease course in people at risk for or already diagnosed with type 1 diabetes. However, any immune-modifying therapy raises a critical safety question: could treatment create delayed harms such as infections, malignancy, allergic phenomena, or new autoimmune disease after the trial has ended?
This question is especially relevant in type 1 diabetes, where many clinical trials have focused not only on efficacy but also on long-term risk-benefit balance. Short-term trial safety is useful, but it cannot fully capture delayed adverse events, particularly when follow-up ends soon after the intervention period. The present study addresses this gap by extending post-trial observation in a large cohort of participants who had previously enrolled in randomized immunotherapy studies.
Study design
This investigation was a long-term observational follow-up of participants from 14 randomized controlled trials conducted through TrialNet and the Immune Tolerance Network Type 1 Diabetes Extension Study. Nearly half of eligible participants, 47%, enrolled in the follow-up program, and 98% answered at least one health-related outcomes question. Participants were observed for a median of 1.78 years after their original trial ended, with interquartile range 0.89 to 4.04 years, and some were followed for as long as 18 years.
The main comparison was between participants who had received active immunotherapy and those who had received placebo in the original trials. Outcomes were self-reported and included moderate to severe hypoglycemia events, hospitalizations, serious infections including COVID-19 infection, new allergic reactions, autoimmune disease, and cancer incidence. For each outcome, the investigators examined whether the frequency differed according to original treatment assignment.
Key Findings
Overall safety signal
The central finding was straightforward: there were no statistically significant differences in any of the self-reported health outcomes between the active therapy and placebo groups. For each question, the number of responses ranged from 209 to 473, and all reported P values were greater than 0.05. In practical terms, the follow-up did not reveal evidence of late-emerging harm attributable to the immunotherapy regimens studied.
This is an important result because immunotherapy trials can produce concern among participants, clinicians, and regulators about whether immune modulation might lead to delayed or cumulative adverse effects. The absence of a signal across several clinically meaningful outcomes is reassuring, especially given the long observation window in some individuals.
Hypoglycemia and hospitalization
Moderate to severe hypoglycemia is a clinically relevant safety endpoint in diabetes studies because it reflects both disease severity and the burden of treatment. Hospitalization, likewise, can capture major acute complications or serious illness. The study found no increase in either outcome among those previously exposed to active immunotherapy. This suggests that, at least in the follow-up period assessed, prior trial therapy did not translate into worsened day-to-day diabetes safety or higher acute care utilization.
Infections, including COVID-19
Because many immunotherapies alter immune responsiveness, infection risk is a major concern. The study specifically evaluated serious infections and included COVID-19 infection in the outcome framework. Again, no difference was observed between active and placebo groups. This is particularly relevant in the post-pandemic era, when patients and clinicians remain attentive to whether prior immune-modifying treatment changes susceptibility to viral illness or severe infection.
That said, self-reported infection outcomes are inherently limited. They are useful for large-scale surveillance, but they do not replace adjudicated infection ascertainment, microbiologic confirmation, or detailed severity grading. Even so, the absence of a broad imbalance is still clinically meaningful.
Autoimmunity, allergy, and cancer
A second safety concern in immunotherapy is whether treatment could trigger new autoimmune disease, allergic reactions, or malignancy. The study did not detect higher rates of any of these outcomes in the active-treatment group. For clinicians, this finding is reassuring because these are among the most feared delayed toxicities in immune-based interventions.
Nevertheless, interpretation should remain cautious. Autoimmune diseases and cancers are relatively uncommon, so a moderate study size and modest follow-up duration may miss small risk increases. The data are best viewed as evidence against a large safety penalty, not proof that long-term risk is zero.
What the statistics mean
The reported P values were greater than 0.05 across all assessed outcomes, indicating no detectable difference in event frequency by treatment assignment. However, lack of statistical significance does not automatically equal equivalence. The study was not necessarily powered to exclude small differences in rare outcomes, and the use of self-reported endpoints may dilute signal detection. In other words, the findings are reassuring but should be interpreted as supportive surveillance data rather than definitive proof of long-term safety for every immunotherapeutic approach.
Expert Commentary
This report is valuable because it reflects a real-world challenge in translational immunology: the benefits of immune intervention must be weighed against the possibility of delayed harm. In type 1 diabetes, this is particularly important because many candidates for immunotherapy are children, adolescents, or young adults who may live with the consequences of treatment for decades. A follow-up system that extends beyond the original trial is therefore not optional; it is an essential part of responsible drug development.
The findings also align with the broader direction of the field. Modern diabetes immunotherapy aims to be more precise and less globally immunosuppressive than older approaches, making a benign long-term safety profile biologically plausible. Still, different agents may carry different risks. Monoclonal antibodies, antigen-specific strategies, cell-based therapies, and combination regimens cannot be assumed to behave identically. The reassuring pattern in this study should therefore encourage continued investigation, not complacency.
Several limitations deserve emphasis. First, outcomes were self-reported rather than uniformly adjudicated, which introduces recall bias and misclassification risk. Second, only 47% of eligible participants enrolled in the follow-up studies, raising the possibility of selection bias if participants with particular outcomes were more or less likely to respond. Third, the median post-trial follow-up was relatively short, even though a subset was observed much longer; rare late toxicities may require far larger cohorts and longer surveillance to detect. Finally, the study aggregates multiple trials and therapies, which strengthens the overall safety message but may obscure agent-specific risks.
Despite these limitations, the work is an important step in building a long-term safety evidence base for type 1 diabetes immunotherapy. For clinicians discussing participation in these trials, the results support a message of cautious optimism: the available follow-up data do not show a clear excess of major late harms, but ongoing monitoring remains necessary.
Clinical Implications
For trial participants, these findings may reduce anxiety about lingering consequences of having received an immune therapy. For investigators, the study underscores the feasibility and value of extension registries and post-trial observational cohorts. For regulators and health systems, it highlights the need to support long-horizon safety infrastructure, especially for therapies intended for pediatric and young adult populations.
In practical counseling, clinicians can now say that current long-term follow-up data are reassuring, but they should avoid overpromising. The right framing is that no major safety signal has emerged so far, not that delayed risk has been definitively ruled out. That distinction is important in evidence-based communication.
Conclusion
Extended follow-up of participants from 14 randomized type 1 diabetes immunotherapy trials did not reveal differences in self-reported serious health outcomes between active treatment and placebo. The results suggest a generally benign long-term side effect profile and strengthen confidence in ongoing development of immune-based therapies for type 1 diabetes. At the same time, continued surveillance remains essential because rare or very late adverse events may only become visible with larger cohorts and longer observation.
Funding and Clinical Trial Information
The abstract identifies the follow-up infrastructure as TrialNet and the Immune Tolerance Network Type 1 Diabetes Extension Study. No explicit funding statement or clinicaltrials.gov identifier was provided in the supplied text. Because the abstract alone does not specify these details, they should be verified in the full article before citation in clinical or policy documents.
References
1. Jacobsen LM, Cuthbertson D, Felton J, Sherr JL, Simmons KM, Hosford J, Ismail HM, Greenbaum CJ, Wherrett DK, Pinckney A, Sanda S, DiMeglio LA, Higdon LE, Evans-Molina C. Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile. Diabetes Care. 2026-06-12. PMID: 42283716.
2. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613.
3. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of teplizumab in delay of type 1 diabetes progression in at-risk individuals. N Engl J Med. 2021;384(1):39-48.
4. Insel RA, Dunne JL, Atkinson MA, et al. Stopping the autoimmune attack that causes type 1 diabetes. Nat Rev Drug Discov. 2015;14(8):508-522.
5. Atkinson MA, Roep BO, Posgai AL, et al. The challenge of translating immune intervention into durable prevention or remission in type 1 diabetes. Diabetes. 2021;70(4):757-766.